CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30

$42.24−0.38 (-0.89%)

Close on Nov 13, 2026Market cap $4.08BP/E –Yield –

CRISPR Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

CRISPR Therapeutics's EV/EBITDA was 10.7× on Jul 29, 2022, against 156.4× a year earlier.

Period	Period end	Value	Change (pts)
2022	Jul 29, 2022	10.7×	+3.0
2021	Dec 31, 2021	7.8×	−148.6
2020	Jul 31, 2020	156.4×	–

Parsed from the XBRL in CRISPR Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CRSP.

Revenue growth-34.3% · median 7.2%

Operating margin-2114.8% · median -315.9%

Net margin-1812.1% · median -282.2%

Advertisement
300 × 250

See a number that looks wrong?